AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14535873 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Number of subjects: 80
Study 14535873 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Number of subjects: 80
Study 10982170 — intervention group
Group type: EXPERIMENTAL
Intervention: Four large multicenter study protocols
Number of subjects: 120
Study 8937280 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (7.5 mg/kg daily for 60 days)
Number of subjects: 130
Study 8937280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 8937280 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 130
Study 8299527 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (5 mg/d, sometimes increased to 10 mg/d after 3 weeks)
Number of subjects: 11
Study 8299527 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (twice daily 12.5 mg, sometimes increased to twice 25 mg after 3 weeks)
Number of subjects: 11
Study 8299527 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 3043570 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation with Guided Imagery (RGI)
Number of subjects: 24
Study 3043570 — intervention group
Group type: COMPARATOR
Intervention: Control (quiet period)
Number of subjects: 24
Study 30989422 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1800796 polymorphism of the IL-6 gene
Number of subjects: 182
Study 30989422 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without MetS)
Number of subjects: 182
Study 28320259 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.025 to 0.2 μg/kg/min continuous infusion)
Number of subjects: 506
Study 28320259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 28320259 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 506
Study 26273134 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane + dexmedetomidine (DISO)
Number of subjects: 49
Study 26273134 — intervention group
Group type: COMPARATOR
Intervention: isoflurane + saline (NISO)
Number of subjects: 49
Study 23043851 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE)
Number of subjects: 26
Study 23043851 — intervention group
Group type: COMPARATOR
Intervention: Spiral enteroscopy (SE)
Number of subjects: 26
Study 21964228 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSS) program, 55 minutes, twice a week for 10 weeks
Number of subjects: 51
Study 21964228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study 19075728 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 60
Study 19075728 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 19075728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 60
Study 19075728 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 60
Study 16573792 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cholesterol diet (300 mg/day)
Number of subjects: 15
Study 16573792 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol diet (1300 mg/day)
Number of subjects: 15
Study 12656549 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 18
Study 12656549 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of propofol
Number of subjects: 18
Study 11008222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (600 mg/day for 8 weeks, followed by 1,000 mg/day for 8 weeks, and then 1,200 mg/day for 8 weeks)
Number of subjects: 39
Study 11008222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11008222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (in second phase for patients who received placebo)
Number of subjects: 39
Study 11008222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 39
Study 8956115 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Naughton's protocol (Protocol B)
Number of subjects: 11
Study 8956115 — intervention group
Group type: COMPARATOR
Intervention: Standard Naughton's protocol (Protocol A)
Number of subjects: 11
Study 1568523 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg cefetamet pivoxil twice daily (n = 18)
Number of subjects: 37
Study 1568523 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg cefetamet pivoxil twice daily (n = 8)
Number of subjects: 37
Study 1568523 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-50 mg/kg amoxycillin/clavulanic acid three times daily (n = 11)
Number of subjects: 37
Study 6486705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with iron
Number of subjects: 0
Study 6486705 — intervention group
Group type: COMPARATOR
Intervention: Plasma ferritin estimations
Number of subjects: 0
Study 6486705 — intervention group
Group type: COMPARATOR
Intervention: Blood haemoglobin estimations
Number of subjects: 0
Study 31145713 — intervention group
Group type: EXPERIMENTAL
Intervention: cPP (central pulse pressure) measured with a 6m long tubing during MRI acquisition
Number of subjects: 38
Study 31145713 — intervention group
Group type: COMPARATOR
Intervention: bPP (brachial pulse pressure) measured with 2 and 6m long tubing
Number of subjects: 38
Study 29550566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily
Number of subjects: 157
Study 29550566 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg daily (4 weeks on/2 weeks off)
Number of subjects: 157
Study 27865358 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg monacolin K from RYR and 200 μg folic acid per day
Number of subjects: 142
Study 27865358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 24385133 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 0
Study 21951325 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin (TI)
Number of subjects: 730
Study 21951325 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 730
Study 19438927 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 75 mg/kg
Number of subjects: 14
Study 19438927 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 150 mg/kg
Number of subjects: 14
Study 19438927 — intervention group
Group type: COMPARATOR
Intervention: NaCl (24 mg/kg, placebo)
Number of subjects: 14
Study 19438927 — intervention group
Group type: EXPERIMENTAL
Intervention: High MSG session
Number of subjects: 14
Study 19438927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MSG session
Number of subjects: 14
Study 19438927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 14
Study 17276178 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day)
Number of subjects: 121
Study 17276178 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 121
Study 15649723 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drain (group a)
Number of subjects: 143
Study 15649723 — intervention group
Group type: COMPARATOR
Intervention: No wound drain (group b)
Number of subjects: 143
Study 12424509 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive management of risk factors such as hypertension, dyslipidemia, and platelet dysfunction in diabetics
Number of subjects: 0
Study 10090633 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week strength training programme (3 sets of 8 repetitions at 80% of one repetition maximum, 3 days a week)
Number of subjects: 32
Study 10090633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 10090633 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week strength training programme
Number of subjects: 32
Study 7812004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH) method
Number of subjects: 10
Study 7812004 — intervention group
Group type: COMPARATOR
Intervention: Conventional G‐banding method
Number of subjects: 10
Study 7812004 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐round nested reverse transcription polymerase chain reaction assay
Number of subjects: 10
Study 2190507 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-HETE
Number of subjects: 10
Study 2190507 — intervention group
Group type: COMPARATOR
Intervention: Diluent (sodium phosphate buffer)
Number of subjects: 10
Study 7032828 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (1‐‐5 mg daily)
Number of subjects: 20
Study 7032828 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment placebo period
Number of subjects: 20
Study 7032828 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of guanfacine
Number of subjects: 20
Study 7032828 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopamide (given concurrently to two patients)
Number of subjects: 20
Study 30433845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component communication-based intervention including presumptive approach, motivational interviewing, and a fact sheet.
Number of subjects: 0
Study 30433845 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component communication-based intervention.
Number of subjects: 0
Study 30433845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 0
Study 28700791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 103
Study 28700791 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 103
Study 28700791 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 103
Study 25887078 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention (20-hour sessions plus follow-up)
Number of subjects: 360
Study 25887078 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 360
Study 24005134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine hydrochloride (5 mL, chirocaine 25 mg/10 mL) soaked PVA sponge
Number of subjects: 41
Study 24005134 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 mL) soaked PVA sponge
Number of subjects: 41
Study 21232620 — intervention group
Group type: EXPERIMENTAL
Intervention: Realigning BioSkin Q Brace with patellar realigning strap applied
Number of subjects: 80
Study 21232620 — intervention group
Group type: COMPARATOR
Intervention: BioSkin Q Brace with patellar realigning strap removed (Control)
Number of subjects: 80
Study 19435690 — intervention group
Group type: EXPERIMENTAL
Intervention: S-GemOx (gemcitabine 1,000 mg/m2, 100-minute infusion D1 followed by oxaliplatin 100 mg/m2, 120-minute infusion)
Number of subjects: 57
Study 19435690 — intervention group
Group type: COMPARATOR
Intervention: GemOx (Gem D1 and ox D2)
Number of subjects: 57
Study 16963671 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg/d for 8 weeks
Number of subjects: 20
Study 16963671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15019314 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 275
Study 15019314 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 275
Study 11407865 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone alone or together with glutamine with or without a low-fat diet containing high-carbohydrate (fibre)
Number of subjects: 47
Study 9208337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus sotalol
Number of subjects: 40
Study 9208337 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus captopril
Number of subjects: 40
Study 7960545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy using colloid agents labelled with gold and technetium (99mTc‐pertechnetate)
Number of subjects: 181
Study 7960545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 181
Study 7960545 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal lymphadenectomy
Number of subjects: 181
Study 3794134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 14
Study 3794134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 14
Study 29019046 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 2772
Study 29019046 — intervention group
Group type: EXPERIMENTAL
Intervention: Live phone call
Number of subjects: 2772
Study 29019046 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages
Number of subjects: 2772
Study 27744424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with eyes moving while fixating on the therapist's moving hand (EM)
Number of subjects: 139
Study 27744424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with eyes fixating on the therapist's nonmoving hand (EF)
Number of subjects: 139
Study 27744424 — intervention group
Group type: COMPARATOR
Intervention: Exposure without explicit visual focus of attention (EC)
Number of subjects: 139
Study 24634285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 0
Study 24634285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23349548 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 154
Study 20102257 — intervention group
Group type: EXPERIMENTAL
Intervention: Online assessment via telerehabilitation application
Number of subjects: 61
Study 18636354 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin combined with oral vancomycin
Number of subjects: 58
Study 18636354 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 58
Study 16549021 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil administration (n-3 polyunsaturated fatty acid rich seal oil)
Number of subjects: 29
Study 16549021 — intervention group
Group type: COMPARATOR
Intervention: Soy oil administration (n-6 fatty acid rich)
Number of subjects: 29
Study 14505773 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) measured by the MOS-HIV questionnaire, specifically physical health summary (PHS) and mental health summary (MHS) scores.
Number of subjects: 957
Study 14505773 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life (HRQOL) measured by the MOS-HIV questionnaire.
Number of subjects: 957
Study 11151866 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of erythromycin i.v.
Number of subjects: 18
Study 11151866 — intervention group
Group type: COMPARATOR
Intervention: 4 mg of i.v. ondansetron (serotonin receptor antagonist) pretreatment
Number of subjects: 18
Study 11151866 — intervention group
Group type: COMPARATOR
Intervention: 12 microg/kg of i.v. atropine pretreatment
Number of subjects: 18
Study 9127848 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated subjects (ACL reconstruction)
Number of subjects: 15
Study 8466682 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg per day (group A)
Number of subjects: 84
Study 8466682 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1000 mg per day (group B)
Number of subjects: 84
Study 3541414 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 120 mg verapamil (t.i.d.)
Number of subjects: 30
Study 3541414 — intervention group
Group type: COMPARATOR
Intervention: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 80 mg propranolol (b.i.d.)
Number of subjects: 30
Study 3541414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three drugs (ISDN, verapamil, propranolol)
Number of subjects: 30
Study 30200103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid soft tissue release (SSTR)
Number of subjects: 17
Study 30200103 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital release (SR)
Number of subjects: 17
Study 30200103 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SSTR and SR
Number of subjects: 17
Study 27348720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 4×5‐min occlusion at 220 mmHg/reperfusion at 0 mmHg
Number of subjects: 21
Study 27348720 — intervention group
Group type: COMPARATOR
Intervention: SHAM - equal to IPC protocol but occlusion at 20 mmHg
Number of subjects: 21
Study 24474434 — intervention group
Group type: EXPERIMENTAL
Intervention: Posted commitment letter intervention (displayed in examination rooms for 12 weeks)
Number of subjects: 954
Study 24474434 — intervention group
Group type: COMPARATOR
Intervention: Standard practice control
Number of subjects: 954
Study 22992762 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of bisphosphonate treatment at two weeks after the operation (Group I, n = 24)
Number of subjects: 50
Study 22992762 — intervention group
Group type: COMPARATOR
Intervention: Initiation of bisphosphonate treatment at three months (Group II, n = 26)
Number of subjects: 50
Study 20367586 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based presentation (n = 30)
Number of subjects: 60
Study 20367586 — intervention group
Group type: COMPARATOR
Intervention: Paper-based information statement (n = 30)
Number of subjects: 60
Study 18272508 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 50
Study 18272508 — intervention group
Group type: COMPARATOR
Intervention: DDD(R) pacing
Number of subjects: 50
Study 16267150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to breast-feed (72% of women had this intention)
Number of subjects: 373
Study 16267150 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude, social influence, and self-efficacy determinants
Number of subjects: 373
Study 16267150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to breast-feed
Number of subjects: 373
Study 16267150 — intervention group
Group type: EXPERIMENTAL
Intervention: ASE model components
Number of subjects: 373
Study 11873025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.17%, 14 ml, administered epidurally during the diurnal period (morning and afternoon)
Number of subjects: 194
Study 11873025 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.17%, 14 ml, administered epidurally during the nocturnal period (night and evening)
Number of subjects: 194
Study 10350384 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg od for 5 days)
Number of subjects: 1057
Study 10350384 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (250 mg qid for 7 days)
Number of subjects: 1057
Study 7858733 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous growth hormone (GH) for 5 months
Number of subjects: 12
Study 7858733 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 men with similar sperm counts)
Number of subjects: 12
Study 1776803 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 40
Study 1776803 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 40
Study 1776803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 6132524 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutol (400 to 800 mg daily)
Number of subjects: 28
Study 6132524 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (200 to 400 mg daily)
Number of subjects: 28
Study 30998402 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-Spanning Augmentation of Single-Row Repair (SSA-SR)
Number of subjects: 71
Study 30998402 — intervention group
Group type: COMPARATOR
Intervention: Single-Row Repair (SR)
Number of subjects: 71
Study 28267790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (1-10 cigarettes per day)
Number of subjects: 636
Study 28267790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (>10 cigarettes per day)
Number of subjects: 636
Study 28267790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 636
Study 28267790 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 636
Study 26316553 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 109
Study 26316553 — intervention group
Group type: COMPARATOR
Intervention: Control (information and reassurance only)
Number of subjects: 109
Study 24387157 — intervention group
Group type: EXPERIMENTAL
Intervention: High aortic pulse wave velocity (aPWV) quartile
Number of subjects: 153
Study 22800876 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reinforcement interventions
Number of subjects: 21
Study 22800876 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reinforcement interventions (randomized studies)
Number of subjects: 21
Study 22800876 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial reinforcement interventions (longer duration, $50 or more per week, at least weekly reinforcement)
Number of subjects: 21
Study 19132569 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-specific communication skills training (n=9)
Number of subjects: 17
Study 19132569 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 17
Study 17578312 — intervention group
Group type: EXPERIMENTAL
Intervention: Liqi Kuanxiong Huoxue method (LKH) in addition to conventional treatment
Number of subjects: 51
Study 17578312 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (nitrate, diltiazem hydrochloride, etc.)
Number of subjects: 51
Study 15224278 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 573
Study 15224278 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg infliximab (group II)
Number of subjects: 573
Study 15224278 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg infliximab at weeks 2 and 6, followed by 10 mg/kg thereafter (group III)
Number of subjects: 573
Study 15224278 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulators
Number of subjects: 573
Study 15224278 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 573